Stanford Biotech Group Podcast

Stanford Biotech Group Podcast

By Stanford Biotechnology GroupScienceLife Sciences
Download on the App Store

Stanford Biotech Group Podcast episodes

  • Who Owns the Discovery? Biotech Patents and AI with Julia Minitti

    What should you think about before sharing a discovery in a preprint, on a conference poster, or with a chatbot? Host Afi Tagnedji sits down with Julia Minitti, a Wilson Sonsini patent partner and former medicinal chemist, to talk about when to file a patent, what investors look for in a biotech startup’s intellectual property, and who gets credit when AI helps design a drug. Julia also shares what drew her from the chemistry bench to patent law.

    Afi Tagnedji is Vice President of Communications for the Stanford Biotechnology Group and a Computational and Systems Cancer biology PhD candidate at Stanford University. Her research focuses on drug design and development.

    The views Julia Minitti expresses in this episode are her own and do not necessarily reflect those of Wilson Sonsini Goodrich & Rosati, its attorneys, or its clients. This episode is for general informational purposes only and does not constitute legal advice. Listening to this episode does not create an attorney-client relationship.


    41 min
  • The Future of Agriculture is Biotech: an Interview with Tim Schnabel at Switch Bioworks

    In this episode of the Stanford Biotech Group Podcast, our Co-VP of Communications, Mikaela Ribi, sits down with Tim Schnabel, founder and CEO of Switch Bioworks, a Stanford spinout engineering microbes to produce sustainable nitrogen fertilizer. Together, we explore his journey from PhD research to entrepreneurship, the challenges of translating scientific discoveries into practical solutions, and what it takes to build a biotechnology company from the ground up.

    41 min
  • World-Class Science. But Where Are Australia’s Biotechs?

    Our guest is Dr. Bob Soh, a partner at Brandon Capital, Australia’s biggest life sciences venture capital firm.

    Bob talks with Rui Yip about why Australia’s strong research base hasn’t produced a bigger biotech industry, and why overseas biotechs often run their Phase 1 trials here. They also cover how veterans of big pharma are helping launch new companies, how the local pool of biotech venture capital is growing, and what’s being done to keep promising companies, manufacturing and know-how in the country as they scale.

    21 min

About Stanford Biotech Group Podcast

From the publisher's feed

The Stanford Biotech Group Podcast is your front-row seat to the people shaping the future of the life sciences. Run by Stanford graduate and professional students across PhD, MD, MBA, and MS…